123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract
Irene Virgolini(Innsbruck Medical University), Peter Valent(Medical University of Vienna), Qing Yang(Guangzhou University of Chinese Medicine), Klaus Kaserer(Medical University of Vienna), P. Hübsch(University of Vienna), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Shuren Li(University of Vienna), Markus Raderer(University of Vienna), Werner Scheithauer(Comprehensive Cancer Center Vienna), M. Leimer(University of Vienna), Amir Kurtaran(University of Vienna), Gabriela Kornek(Medical University of Vienna), Bruno Niederle(Medical University of Vienna), J. Pidlich(Rudolfinerhaus Hospital), P. Angelberger(Seibersdorf Laboratories (Austria))
Cited by 52
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Diagnostic criteria and classification of mastocytosis: a consensus proposal
|Leukemia Research|2001|1.1k